Switch theme
Sign up to access all valuation multiples
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
1996
75.9K+
LTM Revenue $45.9B
LTM EBITDA $19.0B
$232B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Novartis has a last 12-month revenue of $45.9B and a last 12-month EBITDA of $19.0B.
In the most recent fiscal year, Novartis achieved revenue of $57.2B and an EBITDA of $22.9B.
Novartis expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Novartis valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $57.3B | $51.6B | $57.2B | $45.9B | XXX |
| Gross Profit | $40.2B | $37.8B | $43.0B | XXX | XXX |
| Gross Margin | 70% | 73% | 75% | XXX | XXX |
| EBITDA | $18.1B | $20.2B | $22.9B | $19.0B | XXX |
| EBITDA Margin | 32% | 39% | 40% | 41% | XXX |
| Net Profit | $7.7B | $16.4B | $13.2B | XXX | XXX |
| Net Margin | 13% | 32% | 23% | XXX | XXX |
| Net Debt | $20.6B | $12.3B | $19.9B | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Novartis's stock price is CHF 98 (or $108).
Novartis has current market cap of CHF 194B (or $214B), and EV of CHF 210B (or $232B).
See Novartis trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $232B | $214B | XXX | XXX | XXX | XXX | $7.89 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Novartis has market cap of $214B and EV of $232B.
Novartis's trades at 4.6x LTM EV/Revenue multiple, and 11.1x LTM EBITDA.
Analysts estimate Novartis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Novartis and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $232B | XXX | XXX | XXX |
| EV/Revenue | 4.1x | XXX | XXX | XXX |
| EV/EBITDA | 10.1x | XXX | XXX | XXX |
| P/E | 16.2x | XXX | XXX | XXX |
| P/E/Growth | 1.3x | XXX | XXX | XXX |
| EV/FCF | 15.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpNovartis's NTM/LTM revenue growth is 3%
Novartis's revenue per employee for the last fiscal year averaged $0.8M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, Novartis's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Novartis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Novartis and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 40% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 43% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.8M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 19% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 47% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Novartis acquired XXX companies to date.
Last acquisition by Novartis was XXXXXXXX, XXXXX XXXXX XXXXXX . Novartis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Novartis founded? | Novartis was founded in 1996. |
| Where is Novartis headquartered? | Novartis is headquartered in Switzerland. |
| How many employees does Novartis have? | As of today, Novartis has 75.9K+ employees. |
| Who is the CEO of Novartis? | Novartis's CEO is Dr. Vasant Narasimhan. |
| Is Novartis publicy listed? | Yes, Novartis is a public company listed on SWX. |
| What is the stock symbol of Novartis? | Novartis trades under NOVN ticker. |
| When did Novartis go public? | Novartis went public in 2001. |
| Who are competitors of Novartis? | Similar companies to Novartis include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Novartis? | Novartis's current market cap is $214B |
| What is the current revenue of Novartis? | Novartis's last 12-month revenue is $45.9B. |
| What is the current EBITDA of Novartis? | Novartis's last 12-month EBITDA is $19.0B. |
| What is the current EV/Revenue multiple of Novartis? | Current revenue multiple of Novartis is 4.6x. |
| What is the current EV/EBITDA multiple of Novartis? | Current EBITDA multiple of Novartis is 11.1x. |
| What is the current revenue growth of Novartis? | Novartis revenue growth between 2023 and 2024 was 11%. |
| Is Novartis profitable? | Yes, Novartis is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
